论文部分内容阅读
目的:探讨醛酮还原酶1C2(AKR1C2)和组织蛋白酶D(cathepsinD)在膀胱移行细胞癌中的表达及其与膀胱癌病理分级、临床分期的关系。方法:应用免疫组织化学的方法检测AKR1C2和cathepsinD在40例膀胱癌组织和5例正常膀胱组织中的表达,并对比两者表达相关性。结果:40例膀胱癌中AKR1C2阳性表达率为80%,cathepsinD阳性表达率为90%,cathepsinD蛋白表达与膀胱癌病理分级、临床分期呈正相关(r=0.308),AKR1C2蛋白表达在不同膀胱癌病理分级中差异有统计学意义(P<0.05)。AKR1C2蛋白在不同临床分期之间表达差异无统计学意义。结论:结论:AKR1C2和cathepsinD表达特征可以作为膀胱移行细胞癌的诊断和判断预后的参考指标。
Objective: To investigate the expression of AKR1C2 and cathepsin D in bladder transitional cell carcinoma and its relationship with pathological grade and clinical stage of bladder cancer. Methods: The expressions of AKR1C2 and cathepsinD in 40 cases of bladder cancer and 5 cases of normal bladder tissue were detected by immunohistochemistry, and their correlations were analyzed. Results: The positive rate of AKR1C2 in bladder cancer was 80%, the positive rate of cathepsinD was 90%. The protein expression of cathepsin D was positively correlated with the pathological grade and clinical stage of bladder cancer (r = 0.308). The expression of AKR1C2 protein in different pathological types of bladder cancer There was significant difference in grading (P <0.05). AKR1C2 protein expression in different clinical stages showed no significant difference. Conclusions: Conclusion: The expression of AKR1C2 and cathepsinD may serve as a reference for the diagnosis and prognosis of bladder transitional cell carcinoma.